EuroIntervention ads

How does visual assessment compare with standardised evaluation of device success after PCI? In a prespecified analysis of the Multivessel TALENT trial, involving 4,052 coronary lesions, core lab quantitative coronary angiography (QCA) yielded lower device success rates than operator visual assessment (88.0% vs 97.4%). Lesions not meeting QCA-based device success criteria were associated with higher rates of lesion-oriented clinical events at 1 year (12.0% vs 9.1%). 🔗 https://lnkd.in/dwxadmgp

In this prespecified #SMARTCHOICE3 substudy of patients with remote PCI at high ischaemic risk, clopidogrel monotherapy reduced cardiovascular events vs aspirin, with no significant sex-by-treatment interaction, supporting a consistent treatment effect across sexes. https://lnkd.in/daxQB_6s

Angiography-derived radial wall strain (RWS) provides a novel approach to residual risk stratification after PCI. In this post hoc analysis of TARGET All Comers, elevated RWS was independently associated with 5-year adverse events in deferred non-target vessels, with the strongest prognostic value for subsequent revascularisation. 🔗 https://lnkd.in/dwYSE-Yz Simone Fezzi Andreas Baumbach; Helen Parise; Alexandra Lansky; #PCI #CoronaryArteryDisease

In the prespecified HBR substudy of SELUTION DeNovo, a sirolimus-eluting balloon strategy with provisional stenting was compared with systematic DES implantation. At 1 year, rates of target vessel failure, major bleeding, and net adverse clinical events were numerically lower with the SEB strategy. 🔗 https://lnkd.in/dUJ6ZU_B Tuomas Rissanen; simon eccleshall; Florian PD Dr.med. Krackhardt; Tanios Akiki; Carlo Briguori; Alexander den Hartog; Philippe Garot; Jonas Häner; Juan F. Iglesias; Christoph Langer, Ludovic Meunier; Pierre Poustis; Karim Ratib; Manel Sabate; Joanna Wykrzykowska ; Christian Spaulding; philip urban

Transcatheter vacuum-assisted extraction of left heart and aortic arch masses showed promising early effectiveness in this multicentre registry. The observed rate of adverse events suggests the need for careful patient selection and improved procedural safety. 📎 https://lnkd.in/dT54Nfqc Jonathan Fang; Tiberio Frisoli, MD, FACC; Pedro Engel Gonzalez; Junichi Shimamura; HASAN AHMAD; Syed Abbas Haidry, MD, FACC, FSCAI; Gennaro Giustino, MD; Ahmad Jabri ; Ralph Stephan von Bardeleben; Samuel Gregerson; Arturo Giacaman; Michael Chiang; Kent Chak Yu So; Pedro Villablanca

In the SPIRARE II trial, mechanical aspiration thrombectomy with the Vertex Pulmonary Embolectomy System met its prespecified safety and effectiveness endpoints in intermediate-risk pulmonary embolism, with improved right ventricular function and a low rate of major adverse events. https://lnkd.in/ev_yeh25 #PulmonaryEmbolism #MechanicalThrombectomy Sameh Sayfo, MD, MBA, FACC, FSCAI; Joseph Ingrassia; Rohit Amin, MD; Wissam Jaber; Felix Mahfoud; Grzegorz Kopec;